Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

Karin Jordan, Axel F Grothey, Wilfried Grothe, Thomas Kegel, Hans Heinrich Wolf, Hans Joachim Schmoll

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalEuropean Journal of Haematology
Volume74
Issue number3
DOIs
StatePublished - Mar 2005
Externally publishedYes

Fingerprint

Lymphomatoid Granulomatosis
Interferon-alpha
Lymphoproliferative Disorders
Therapeutics
Human Herpesvirus 4
Antiviral Agents
Adrenal Cortex Hormones
B-Lymphocytes
Radiotherapy
Biopsy
Drug Therapy
Rituximab
Neoplasms

Keywords

  • CD20
  • EBV-associated lymphoproliferative disease
  • Liebow granulomatosis
  • Lymphomatoid granulomatosis
  • Mediastinal bulk
  • Rituximab

ASJC Scopus subject areas

  • Hematology

Cite this

Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. / Jordan, Karin; Grothey, Axel F; Grothe, Wilfried; Kegel, Thomas; Wolf, Hans Heinrich; Schmoll, Hans Joachim.

In: European Journal of Haematology, Vol. 74, No. 3, 03.2005, p. 263-266.

Research output: Contribution to journalArticle

Jordan, Karin ; Grothey, Axel F ; Grothe, Wilfried ; Kegel, Thomas ; Wolf, Hans Heinrich ; Schmoll, Hans Joachim. / Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy. In: European Journal of Haematology. 2005 ; Vol. 74, No. 3. pp. 263-266.
@article{f3e8f5d05a234637af572eaf56bf535d,
title = "Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy",
abstract = "Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.",
keywords = "CD20, EBV-associated lymphoproliferative disease, Liebow granulomatosis, Lymphomatoid granulomatosis, Mediastinal bulk, Rituximab",
author = "Karin Jordan and Grothey, {Axel F} and Wilfried Grothe and Thomas Kegel and Wolf, {Hans Heinrich} and Schmoll, {Hans Joachim}",
year = "2005",
month = "3",
doi = "10.1111/j.1600-0609.2004.00367.x",
language = "English (US)",
volume = "74",
pages = "263--266",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Successful treatment of mediastinal lymphomatoid granulomatosis with rituximab monotherapy

AU - Jordan, Karin

AU - Grothey, Axel F

AU - Grothe, Wilfried

AU - Kegel, Thomas

AU - Wolf, Hans Heinrich

AU - Schmoll, Hans Joachim

PY - 2005/3

Y1 - 2005/3

N2 - Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.

AB - Lymphomatoid granulomatosis is a rare Epstein-Barr virus (EBV)-positive-B-cell lymphoproliferative disorder. Treatment options include corticosteroids, antiviral therapy, interferon-alpha and chemotherapy. However, long-term prognosis is poor and no therapeutic standard has been established yet. In a 21-year-old woman, a biopsy of mediastinal mass revealed lymphomatoid granulomatosis. Combined therapy with valganciclovir and interferon-alpha proved ineffective. In view of the CD20 expression of the tumor cells, monotherapy with rituximab was intiated. After 3 months a complete remission was achieved. Rituximab was continued for another 6 months with subsequent consolidation radiotherapy. This is the first report of an enduring complete remission (20 months) of a non-CNS lymphomatoid granulomatosis treated with rituximab.

KW - CD20

KW - EBV-associated lymphoproliferative disease

KW - Liebow granulomatosis

KW - Lymphomatoid granulomatosis

KW - Mediastinal bulk

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=14044256512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14044256512&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2004.00367.x

DO - 10.1111/j.1600-0609.2004.00367.x

M3 - Article

C2 - 15693798

AN - SCOPUS:14044256512

VL - 74

SP - 263

EP - 266

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 3

ER -